Neuro-Oncology News

A novel nanomedicine agent known as BXQ-350 has demonstrated the ability to cross the blood-brain barrier in patients with solid tumors, according to study results.

The addition of lomustine to bevacizumab failed to confer a survival advantage for the treatment of progressive glioblastoma in a phase 3 EORTC clinical trial, a finding that is likely to change research priorities for this disease.

More than half of young adults with cancer reported ongoing problems with sexual functioning in the first 2 years following their diagnosis, according to an investigational study published in Cancer.

The FDA granted orphan drug designation to GDC-084 for the treatment of patients with glioblastoma multiforme, the most aggressive form of primary brain cancer, according to the agent’s manufacturer.

The Alliance for Cancer Gene Therapy awarded $1.3 million worth of grants to fund three clinical trials that will evaluate immunotherapy and virotherapy for glioblastoma, sarcoma and ovarian cancer.

This weekend’s Super Bowl LII showdown between the New England Patriots and Philadelphia Eagles will coincide with World Cancer Day, an international observance held every Feb. 4 to emphasize the importance of cancer prevention, detection and treatment.

A majority of neurosurgeons believe aging members of their field should undergo additional testing or evaluation beyond standard Maintenance of Certification examinations, according to results of a survey published in Mayo Clinic Proceedings.

The addition of tumor-treated fields to standard therapy with temozolomide prolonged deterioration-free survival without negatively influencing health-related quality of life among patients with glioblastoma, according to a secondary analysis of a phase 3 clinical trial published in JAMA Oncology.

Five-year survival for the most common 18 cancers remained highest globally for the United States, Canada, Australia and New Zealand, followed by Finland, Iceland, Norway and Sweden, according to data through 2014 from CONCORD-3.

Mark A. Israel, MD, has been appointed executive director of the Israel Cancer Research Fund, the largest nonprofit organization dedicated to funding cancer research in Israel.